These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
https://s.yimg.com/ny/api/res/1.2/tN4DHENaEkTTyqRTnDte_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MA--/https://media.zenfs.com/en/investopedia_245/31b50cbad857b6fe7249cc6609c64985
https://finance.yahoo.com/news/two-stocks-plunged-eli-lilly-212150177.html
Shares of Insulet and DexCom, two companies that provide medical devices for patients managing diabetes, tumbled after a study showed that a popular drug made by Eli Lilly significantly lowers the risk of developing type 2 diabetes. The results of the study demonstrate another benefit of tirzepatide and other drugs known as GLP-1 receptor agonists, which could be a concern for companies that make products to treat related conditions.